PD-002 Mucosal Healing with Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium.

Kochhar, Gursimran; Parikh, Malav; Chaudrey, Khadija; More

Inflammatory Bowel Diseases . 23:S6, February 2017.

P-040 Assessing Risk Factors Predicting Loss of Response to Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium.

Shmidt, Eugenia; Winters, Adam; Katta, Leah; More

Inflammatory Bowel Diseases . 23:S18, February 2017.

P-049 Validated Prediction Model for Clinical Remission with Vedolizumab in Crohn's Disease: Post Hoc Analysis of GEMINI II Clinical Trial.

Dulai, Parambir; Boland, Brigid; Singh, Siddharth; More

Inflammatory Bowel Diseases . 23:S21, February 2017.

How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease

Dulai, Parambir S.; Singh, Siddharth; Casteele, Niels V.; More

Inflammatory Bowel Diseases . 22(4):998-1009, April 2016.

P-033 YI Efficacy and Safety of Vedolizumab for Inflammatory Bowel Disease in Clinical Practice.

Chaudrey, Khadija; Lightner, Amy; Singh, Siddharth; More

Inflammatory Bowel Diseases . 22:S19-S20, March 2016.

Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis

Chandar, Apoorva K.; Singh, Siddharth; Murad, Mohammad Hassan; More

Inflammatory Bowel Diseases . 21(7):1695-1708, July 2015.

Effect of Ursodeoxycholic Acid Use on the Risk of Colorectal Neoplasia in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Systematic Review and...

Singh, Siddharth; Khanna, Sahil; Pardi, Darrell S.; More

Inflammatory Bowel Diseases . 19(8):1631-1638, July 2013.